Palisade Bio, INC.: directors' dealings · United States · SEC (Form 4)

About Palisade Bio, INC.

Palisade Bio, Inc. (NASDAQ: PALI) is a clinical-stage biopharmaceutical company headquartered in Carlsbad, California, in the United States and listed on the Nasdaq Capital Market. For investors, the company stands out as a highly focused development story rather than a diversified commercial biotech. Its core strategy is built around a differentiated oral prodrug platform centered on PDE4 biology, with the aim of improving tolerability, pharmacology, and convenience for patients with chronic inflammatory and fibrotic diseases. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001357459/000135745926000004/pali-20251231.htm?utm_source=openai)) The company’s lead asset is PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed to be selectively activated in the terminal ileum and colon. The logic of the program is to concentrate activity at the site of disease while limiting systemic exposure, which may help reduce the class-related CNS and gastrointestinal side effects that have historically constrained PDE4 therapies. Palisade Bio’s disclosed development focus is inflammatory bowel disease, especially ulcerative colitis and fibrostenotic Crohn’s disease, with the platform concept potentially expandable to other inflammatory and fibrotic indications. ([palisadebio.com](https://palisadebio.com/about-us-overview/?utm_source=openai)) In competitive terms, Palisade Bio fits the profile of a small-cap U.S. biotech whose valuation is driven primarily by clinical data, regulatory milestones, and funding execution. The company does not yet have a commercial product base or meaningful recurring operating revenue; instead, its investment case depends on whether PALI-2108 can demonstrate a compelling efficacy/safety profile and a clear differentiation versus existing IBD treatments. That makes the shares on the Nasdaq particularly sensitive to trial readouts, protocol updates, and capital raises. ([palisadebio.com](https://palisadebio.com/pipeline-overview/?utm_source=openai)) Recent company updates have been constructive. In 2025 and 2026, Palisade Bio reported positive Phase 1a and Phase 1b results for PALI-2108, including additional topline data in fibrostenotic Crohn’s disease and ulcerative colitis. The latest quarterly update also highlighted continued clinical progress and anticipated Phase 2 trial initiations in 2026, signaling that management is attempting to move the lead program from proof-of-concept into later-stage development. For investors in the United States-listed Nasdaq name, the story remains a classic clinical catalyst pipeline: high upside if execution continues, but also elevated binary risk typical of development-stage biotech. ([palisadebio.com](https://palisadebio.com/palisade-bio-reports-first-quarter-2026-financial-results-and-highlights-continued-clinical-progress-of-pali-2108/?utm_source=openai))